CRISPR Therapeutics (CRSP) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
011M22M34M45M56M68M79M90MQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Operating Expenses

Research And Development ExpensesGeneral And Administrative ExpensesOther Expenses
038M75M112M150M188M225M262M300MQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025

EBITDA

EBITDA
-300M-262M-225M-187M-150M-112M-75M-37M1Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

EPS

Revenue Variation (%)

Revenue Variation
-200-175-150-125-100-74-49-241Q1 2025Q2 2025Q4 2025

Income Variation (%)

Gross Profit VariationOperating Income Variation
0255075100125150175200Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Revenue YoY Variation (%)

Revenue YoY Variation
-200-164-128-91-55-19185490Q4 2024Q1 2025Q2 2025Q4 2025

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
075150225300375450525600Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Price-to-Earning Ratio

P/E Ratio
-30-26-22-18-14-11-7-31Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Income Breakdown

Operating IncomeTotal Other Income Expenses NetNet Income
05M10M15M20M25M30M35M40MQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
0255075100125150175200Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
062M125M188M250M312M375M438M500MQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
050M100M150M200M250M300M350M400MQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025
🏦 Balance Sheet
📈 Key Metrics